APGE Stock Summary and Trading Ideas (Apogee Therapeutics | NASDAQ:APGE)

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.

Apogee Therapeutics trades on the NASDAQ stock market under the symbol APGE.

As of October 31, 2024, APGE stock price declined to $52.09 with 180,435 million shares trading.

APGE has a beta of 2.36, meaning it tends to be more sensitive to market movements. APGE has a correlation of 0.11 to the broad based SPY ETF.

APGE has a market cap of $2.95 billion. This is considered a Mid Cap stock.

The top ETF exchange traded funds that APGE belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.

APGE has outperformed the market in the last year with a return of +212.3%, while the SPY ETF gained +39.2%. In the last 3 month period, APGE beat the market returning +8.7%, while SPY returned +5.8%. However, in the most recent 2 weeks APGE has underperformed the stock market by returning -8.3%, while SPY returned -1.9%.

APGE support price is $53.01 and resistance is $56.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APGE shares will trade within this expected range on the day.